Dr. Hannan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Rd
Atlanta, GA 30322Phone+1 404-441-3167
Education & Training
- Emory University School of MedicineResidency, Internal Medicine, 2013 - 2016
- Georgetown University School of MedicineClass of 2013
Certifications & Licensure
- GA State Medical License 2023 - 2026
- WA State Medical License 2016 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study.Michael Li, Lindsay M Hannan, Lipika Goyal, Andrea G Bocobo, Anna L Parks
Therapeutic Advances in Medical Oncology. 2024-01-01 - 1 citationsUse of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malign...Stacey A Cohen, Susan Veleber, Jonathan Siman, Katherine A Guthrie, Kerry McMillen
Contemporary Clinical Trials. 2023-08-01 - 1 citationsPerioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.Andrew L Coveler, Venu G Pillarisetty, Wui-Jin Koh, David B Zhen, James O Park
Pancreas. 2023-05-01
Lectures
- Clinical predictors of progression of a hepatic lesion from Li-RADS (LR) 3 to LR5 among patients (pts) at risk of hepatocellular carcinoma (HCC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Clinical predictors of radiographic progression of a hepatic lesion from Li-RADS 3 to Li-RADS 5 among a population of individuals at high risk of hepatocellular carcin...2019 ASCO Annual Meeting - 6/1/2019
- A retrospective analysis of clinical outcomes among patients with infiltrative hepatocellular carcinoma (iHCC): A single institution study.2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: